ClinicalTrials.gov record
Terminated Phase 1 Interventional Results available

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

ClinicalTrials.gov ID: NCT02468557

Public ClinicalTrials.gov record NCT02468557. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 9:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Study identification

NCT ID
NCT02468557
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
16 participants

Conditions and interventions

Interventions

  • Idelalisib Drug
  • Nab-paclitaxel Drug
  • mFOLFOX6 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2015
Primary completion
Apr 26, 2016
Completion
Apr 26, 2016
Last update posted
Apr 1, 2021

2015 – 2016

United States locations

U.S. sites
9
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
Scottsdale Healthcare Clinical Research Institute Scottsdale Arizona 85258
Cedars Sinai Medical Center Los Angeles California 90048
University of Colorado Cancer Center Aurora Colorado 80045
Georgetown University Washington D.C. District of Columbia 20007
Indiana University Goshen Center for Cancer Care Goshen Indiana 46506
Dana Farber/ Harvard Cancer Institute Boston Massachusetts 02215
University of Rochester Rochester New York 14642
Greenville Hospital System Greenville South Carolina 29605
Mary Crowley Medical Research Center Dallas Texas 75230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02468557, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2021 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02468557 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →